Cerebrolysin Adverse Reactions Ineffective; in patients with systemic cyanosis, unconsciousness, fecal incontinence within 2 hours, thus considering Cerebrolysin-induced anaphylactic shock. Symptoms disappeared after oxygen, dehydration, hormonal, and other rescue measures such as fluid therapy for severe headache as reported by Yan Zhenyong and others. One case involved a 43-year-old patient who was given Cerebrolysin (20ml mixed with 10% glucose solution [500ml]) intravenously due to cerebral infarction sequelae, once daily (qd). The patient experienced headaches starting on the first day, but this was not given much attention. On the second day, when the Cerebrolysin dose was increased to 30ml, the patient had severe headaches. Cerebrolysin was then discontinued, other medications were administered, and the headache symptoms resolved, returning to normal after 3 days.
Progress in Pharmaceutical Sciences 2001, 25(3), 3 Mental Disorders: Yanchun Lei reported a patient admitted for right lower extremity barriers. Vasodilators, blood dilution, anticoagulants, and intravenous infusion of Cerebrolysin (20ml, qd) were administered. After 2 days of treatment, psychiatric symptoms emerged, including irritability, incoherent speech, hallucinations, and visual hallucinations. The infusion was stopped, and diazepam and chlorpromazine were given as antipsychotic drugs. Psychiatric symptoms disappeared after 24 hours. After one week, saline 250ml plus 20ml of Cerebrolysin was administered intravenously for 10 hours, and the above-mentioned psychiatric symptoms recurred.
Liver Transaminase Levels: Drainage Hung et al reported a case of dizziness, tremor, and vertigo diagnosed as cerebral arteriosclerosis. Intravenous Cerebrolysin (20ml, qd) was administered along with oral Sibelium (flunarizine) and nimodipine for 15 days. The patient felt fatigue and poor appetite. Liver function tests showed ALT 60U/L. The patient had a history of liver disease. Due to paroxysmal dizziness, Sibelium was taken, but no symptoms occurred. Thus, it was suspected that Cerebrolysin caused the issue. After discontinuation and liver treatment, liver function returned to normal.
Urinary Retention: Limei Qing et al reported a male patient, aged 52, who underwent intravenous infusion of Cerebrolysin (20ml, qd) due to cerebral infarction sequelae. Dysuria occurred two days later, which returned to normal after stopping the medication. When the brain live cable was reapplied, the patient again experienced difficulty urinating, leading to inability to urinate after two days. After drug withdrawal and symptomatic treatment, the condition returned to normal after seven days.
Peripheral Neuralgia: Fan Huaixing reported that in hemiplegic patients, except for one on the right side, Cerebrolysin (10ml mixed with 5% glucose solution) was administered intravenously. Five minutes after the infusion, the patient felt needle-like pain throughout the body. After stopping the infusion, the symptoms disappeared shortly. The next day, similar symptoms reoccurred upon using the drug, suggesting peripheral neuropathic pain caused by Cerebrolysin factors.
Epilepsy: Ma Guifang [C9] reported that one patient with post-traumatic epilepsy experienced sudden convulsions in all limbs three days after intravenous Cerebrolysin administration, lasting 2-3 minutes, with intermittent focal convulsions. Antiepileptic treatment relieved the symptoms within 20 minutes. Another report involved a patient without a history of epilepsy who developed grand mal epilepsy after 13 days of daily intravenous drip of Cerebrolysin. Symptomatic treatment restored consciousness after 15 minutes.